|
Sex (male/female)
|
19/19 (50.0/50.0%)
|
33/19 (60.0/50.0%)
|
0.3982 (a)
|
|
Age (years)
|
65.0 (10.8)
|
64.0 (10.6)
|
0.6776 (b)
|
|
BMI (kg/m2)
|
30.1 (6.0)
|
29.7 (4.6)
|
0.7069 (b)
|
|
Systolic blood pressure (mmHg)
|
140.1 (16.3)
|
137.7 (15.2)
|
0.4653 (b)
|
|
Diastolic blood pressure (mmHg)
|
79.9 (9.5)
|
76.6 (8.8)
|
0.0885 (b)
|
|
Total cholesterol (mg/dL)
|
166.2 (32.5)
|
163.6 (30.8)
|
0.7034 (b)
|
|
Triglycerides (mg/dL)
|
148.0 (90.2)
|
153.7 (101.5)
|
0.7816 (b)
|
|
LDL cholesterol (mg/dL)
|
88.8 (34.1)
|
91.8 (27.8)
|
0.6394 (b)
|
|
HDL colesterol (mg/dL)
|
51.7 (19.6)
|
43.8 (11.5)
|
0.0318 (b)
|
|
Time since diagnosis (years)
|
14.5 (8.9)
|
17.3 (8.0)
|
0.1231 (b)
|
|
≤ 2 years
|
3 (7.9%)
|
0 (0.0%)
|
0.0302 (c)
|
|
2.1 to 5 years
|
3 (7.9%)
|
2 (3.6%)
|
|
5.1 to 10 years
|
6 (15.8%)
|
8 (14.5%)
|
|
> 10 years
|
26 (68.4%)
|
45 (81.8%)
|
|
HbA1c (%)
|
7.8 (0.5)
|
8.0 (0.5)
|
0.0912 (b)
|
|
HbA1c (mmol/mol)
|
62 (5)
|
64 (5)
|
|
Treatment with basal insulin: final dose (units/day)
|
31.1 (16.1)
|
31.1 (17.6)
|
0.9869 (a)
|
|
Years of treatment
|
5.0 (4.7)
|
5.6 (4.4)
|
0.5474 (b)
|
|
Treatment with ADO
|
33 (86.8%)
|
49 (89.1%)
|
0.7543 (a)
|
|
Years of treatment
|
9.2 (7.5)
|
11.7 (7.1)
|
0.1283 (b)
|
|
Treatment with metformin
|
30 (78.9%)
|
45 (81.8%)
|
0.7927 (a)
|
|
Years of treatment
|
9.8 (7.6)
|
10.4 (6.6)
|
0.7361 (b)
|
|
Treatment with DPP-4 Inhibitor
|
8 (21.1%)
|
20 (36.4%)
|
0.1673 (a)
|
|
Years of treatment
|
1.9 (1.5)
|
2.6 (1.8)
|
0.2983 (b)
|
|
Treatment with sulfonylurea
|
8 (21.1%)
|
21 (38.2%)
|
0.1110 (a)
|
|
Years of treatment
|
6.7 (4.9)
|
12.7 (7.2)
|
0.0379 (b)
|
